Preview

Вестник дерматологии и венерологии

Расширенный поиск

Патогенетические аспекты лечения больных псориазом

https://doi.org/10.25208/0042-4609-2014-0-5-86-90

Полный текст:

Аннотация

Отмечены высокие распространенность псориаза и заболеваемость им, значимое снижение качества жизни, психосоциальная дезадаптация больных, представлены некоторые особенности патогенеза псориаза с учетом роли иммунных механизмов и связь заболевания с другими хроническими процессами в организме, из-за чего псориаз рассматривается как полиморбидное состояние. Полиморбидность псориаза является важным фактором при выборе терапии, особенно для больных с тяжелыми формами болезни.

Об авторах

В. В. Чикин
ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России
Россия


Л. Ф. Знаменская
ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России
Россия


А. А. Минеева
ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России
Россия


Список литературы

1. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009: 361 (5): 496 -509.

2. Elder J.T. et al. Molecular dissection of psoriasis: integrating genetics and biology. J. Invest. Dermatol. 2010: 130, 1213 -1226.

3. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007 Jul 21; 370 (9583): 263 -71.

4. L.F. Znamenskaya, L.Ye. Melekhina, Ye.V. Bogdanova, A.A. Mineye. Psoriasis incidence and prevalence in the Russian Federation. Vestn Dermatol Venerol 2012; (5): 20-29. [Знаменская Л.Ф., Мелехина Л.Е., Богданова Е.В., Минеева А.А. Заболеваемость и распространенность псориаза в Российской Федерации. Вестник дерматологии и венерологии 2012 (5): 20-29].

5. Pujola R.M., Puiq L., Daudén E. Mental health selfassessment in patients with moderate to severe psoriasis: an observational, multicenter study of 1164 patients in Spain (the VACAP Study). Actas Dermosifiliogr. 2013 Dec; 104 (10): 897-903.

6. Bouguéon K., Misery L. Depression and psoriasis. Ann Dermatol Venereol. 2008;135: Suppl 4: S254-8.

7. Mudigonda P., Mudigonda T., Feneran A.N., Alamdari H.S., Sandoval L., Feldman S.R. (October 2012). Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol Online J 18 (10): 1.

8. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006; 444: 860-7S.

9. Loo K.F., Yeung K.H., Ho K.M., Lo K.K. Cardiovascular comorbidities in psoriasis Hong Kong J. Dermatol. Venereol. (2010) 18, 72-81.

10. Ludwig R.J., Herzog C., Rostock A., Ochsendorf F.R., Zollner T.M., Thaci D. et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-6.

11. El-Mongy S., Fathy H., Abdelaziz A., Omran E., George S., Neseem N., et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol 2009 Nov 2. [Epub ahead of print] online early assessed on 31st March 2010.

12. Balci D.D., Balci A., Karazincir S., Ucar E., Iyigun U., Yalcin F. et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 1-6.

13. Полотебнов А.Г. Дерматологические исследования. СПб. 1886-1887; Т. 1/2: С. 300 -350.

14. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.

15. Gelfand J.M., Dommasch E.D., Shin D.B., Azfar R.S., Kurd S.K., Wang X. et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129: 2411-8.

16. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012; 26 Suppl 2: 3-11.

17. Papadavid E., Vlami K., Dalamaga M., Giatrakou S., Theodoropoulos K., Gyftopoulos S., Stavrianeas N., Papiris S., Rigopoulos D. Sleep apnea as a comorbidity in obese psoriasis patients: a cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role? J Eur Acad Dermatol Venereol 2013; 27: 820-826.

18. Dalamaga M., Papadavid E., Vlami K. Unmasking the Janus face of the association between psoriasis, metabolic syndrome and obstructive sleep apnea. Sleep Breath 2013; 17: 449-450.

19. Boehncke W.H., Boehncke S., Tobin A.M., Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011, Apr; 20 (4): 303-307.

20. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35.

21. Cohen A.D., Weitzman D., Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010; 90: 23-6.

22. Wakkee M., Thio H.B., Prens E.P., Sijbrands E.J., Neumann H.A. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190: 1-9.

23. Dreiher J., Weitzman D., Davidovici B., Shapiro J., Cohen A.D. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008; 88: 561-5.

24. Mallbris L., Granath F., Hamsten A., Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-21.

25. Love T.J., Qureshi A.A., Karlson E.W. et al. Prevalence of the metabolic syndrome in psoriasis: results from the national health and nutrition examination survey, 2003-2006. Arch Dermatol. 2011, Apr; 147 (4): 419- 424.

26. Cheng J., Kuai D., Zhang L., Yang X., Qiu B. Psoriasis increased the risk of diabetes: a meta-analysis. Arch Dermatol Res 2012; 304: 119-125.

27. Akoglu H., Dede F., Akoglu G. et al. Membranoproliferative glomerulonephritis associated with psoriasis vulgaris. Ren Fail 2009, 31: 858-861.

28. Abuabara K., Azfar R.S., Shin D.B., Neimann A.L., Troxel A.B., Gelfand J.M. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-92.

29. Zadrazil J., Tichý T., Horák P., Nikorjaková I., Zima P., Krejcí K., Strébl P. IgA nephropathy associated with psoriasis vulgaris: a contribution to the entity of 'psoriatic nephropathy'. J Nephrol. 2006 May-Jun; 19 (3): 382-6.

30. Singh N.P., Prakash A., Kubba S., Ganguli A., Singh A.K., Sikdar S. et al. Psoriatic nephropathy- does an entity exist? Ren Fail 2005; 27: 123-7.

31. Archier E., Devaux S., Castela E. et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 22-31.

32. Naldi L., Griffiths CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615.

33. Menter A., Gottlieb A., Feldman S.R. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58 (5): 826-50.

34. Leonardi C.L., Powers J.L., Matheson R.T. et al.; for the Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.5.

35. Gottlieb A.B., Evans R., Li S. et al. Infliximab induction therapy for patients with severe plaquetype psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.6.

36. Gordon K.B., Langley R.G., Leonardi C. et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and openlabel extension study. J Am Acad Dermatol 2006; 55: 598-606.7.

37. Krueger G.G., Langley R.G., Leonardi C. et al.; for the CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-92.8.

38. Leonardi C.L., Kimball A.B., Papp K.A. et al.; for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.

39. Abuabara K., Wan J., Troxel A.B. et al. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013; 68: 262-9.

40. Gottlieb A., Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis 2013 Oct; 5 (5): 277-285.

41. Kurzeja M., Rudnicka L., Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol 2011, Apr 1; 12 (2): 113-125.

42. Laws P.M., Warren R.B. Ustekinumab for the treatment of psoriasis. Expert Rev Clin Immunol 2011, Mar; 7 (2): 155-64.

43. Yeilding N., Szapary P., Brodmerkel C. et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci. 2011, Mar; 1222 (1): 30-39.

44. Hsu L., Snodgrass B.T., Armstrong A.W. Anti-drug Antibodies in Psoriasis: A Systematic Review. Br J Dermatol 2013 Oct 1.

45. Kimball AB1, Papp K.A., Wasfi Y. et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec; 27 (12): 1535-45.

46. Reich K., Langley R.G., Lebwohl M. et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011, Apr; 164 (4): 862-872.

47. Langley R.G., Feldman S.R., Han C., Schenkel B., Szapary P., Hsu M.C., Ortonne J.P., Gordon K.B., Kimball A.B. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.


Для цитирования:


Чикин В.В., Знаменская Л.Ф., Минеева А.А. Патогенетические аспекты лечения больных псориазом. Вестник дерматологии и венерологии. 2014;(5):86-90. https://doi.org/10.25208/0042-4609-2014-0-5-86-90

For citation:


Chikin V.V., Znamenskaya L.F., Mineyeva A.A. Pathogenic aspects of treatment of psoriatic patients. Vestnik dermatologii i venerologii. 2014;(5):86-90. (In Russ.) https://doi.org/10.25208/0042-4609-2014-0-5-86-90

Просмотров: 295


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0042-4609 (Print)
ISSN 2313-6294 (Online)